Bacterial resistance to most antibiotics has presented an enormous problem to solve for mankind. In the last decade, there have been increased efforts to identify new antibiotic targets or to develop novel chemical scaffolds to inhibit known drug targets in bacteria. It is just over four years since a group at Merck reported the identification of a novel class of antibiotics called platensimycin [1] or platencin,[2] which are FabF/H inhibitors and ...
